BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
EPKINLY (epcoritamab-bysp) by Genmab is cd20-directed antibody interactions [moa]. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPKINLY (epcoritamab-bysp) is a bispecific CD20-directed CD3 T cell engager approved by the FDA in May 2023 for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It works by simultaneously binding CD20 on B lymphoma cells and CD3 on T cells, thereby redirecting patient T cells to attack and kill malignant B cells. This novel mechanism represents a significant advancement in immuno-oncology for difficult-to-treat hematologic malignancies.
Growth
Early commercial stage product with growth trajectory; moderate competitive pressure (score: 30) suggests expanding team investment in sales, medical affairs, and market access roles.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Bispecific CD20-directed CD3 T Cell Engager
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EPKINLY represents a growth-stage, innovation-driven product in rare hematologic oncology, offering career exposure to complex bispecific mechanisms, high-touch oncology sales, and sophisticated payer negotiations. Positions offer accelerated visibility and autonomy in a specialized, fast-moving therapeutic area with significant unmet need.
Brand Manager
Worked on EPKINLY at Genmab? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.